- Home
- SWZ vs GANX Comparison
SWZ vs GANX Comparison
Compare SWZ & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SWZ | GANX |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 76.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SWZ | GANX |
|---|---|---|
| Price | $5.95 | $1.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 45.5K | ★ 761.6K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.84 | $1.41 |
| 52 Week High | $6.43 | $4.34 |
Technical Indicators
Market Signals| Indicator | SWZ | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 42.90 |
| Support Level | $5.88 | $1.66 |
| Resistance Level | $6.00 | $2.15 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 46.22 | 16.92 |
Price Performance
Historical ComparisonAbout SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. It actively manages investment solutions spanning public and private markets, wealth management, and Solutions.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.